Immune checkpoint inhibitors in SARS-COV-2 infected cancer patients: the spark that ignites the fire?
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Since December 2019, a novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), initially reported un Wuhan, China, rapidly spread in other 114 countries worldwide, becoming pandemic. In general, COVID-19 is acute resolved disease but it can also be deadly, mainly in older people and those with underlying medical conditions, such as cardiovascular disease and cancer. Cancer patients are at high risk of developing severe COVID-19 illness, probably due to their immunosuppressive state also favoured by anticancer treatments, including chemotherapy and surgery. To date, limited evidence have been available on the relationship between SARS-CoV-2 infection and treatment with immune checkpoint inhibitors (ICI) such as anti-programmed-cell-death-protein 1 (PD-1) and programmed-cell-death-ligand 1 (PD-L1) monoclonal-antibodies, which have notably improved the survival of lung cancer patients. (…)
Lung Cancer , résumé, 2019